Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome

Srdan Verstovsek, Elihu Estey, Taghi Manshouri, Francis J. Giles, Jorge Cortes, Miloslav Beran, Anna Rogers, Michael Keating, Hagop Kantarjian, Maher Albitar

Research output: Contribution to journalArticle

Abstract

We have previously reported that high levels of cellular vascular endothelial growth factor (VEGF) protein correlated with short survival of patients with acute myeloid leukaemia (AML). As VEGF exerts its effects via two receptors, VEGF receptor 1 (VEGFR-1) and VEGFR-2, we evaluated the significance of VEGFR-1 and VEGFR-2 protein levels in AML and myelodysplastic syndrome (MDS), and their relationship to VEGF protein levels. Western blot analysis and radioimmunoassay confirmed and quantified specific protein levels in bone marrow samples from 41 MDS and 66 AML previously untreated patients. VEGFR-1 levels were significantly higher in AML than in MDS (P = 0.0004), but no significant difference was found in the VEGFR-2 levels (P = 0.5). No significant correlation between VEGFRs levels and duration of survival was found. VEGF protein levels were significantly higher in MDS than in AML (P < 0.0001). A Cox proportional-hazard regression model showed increasing VEGF levels to significantly correlate with shorter survival of patients with MDS (P = 0.008), a finding similar to our previous report of the inverse relationship between VEGF levels and survival of AML patients. We found a significant correlation between VEGF and VEGFR-2 levels in both AML and MDS (P < 0.0000001 and P < 0.0002 respectively) but not between VEGF and VEGFR-1 levels. These data suggest that VEGF expression, rather than the expression of its receptors, is the determining factor in the biological behaviour of AML and MDS, and that VEGFRs are differentially expressed in AML and MDS.

Original languageEnglish (US)
Pages (from-to)151-156
Number of pages6
JournalBritish Journal of Haematology
Volume118
Issue number1
DOIs
StatePublished - Jul 27 2002
Externally publishedYes

Fingerprint

Vascular Endothelial Growth Factor Receptor-1
Vascular Endothelial Growth Factor Receptor-2
Myelodysplastic Syndromes
Acute Myeloid Leukemia
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factor Receptor
Survival
Proteins
Biological Factors
Proportional Hazards Models
Radioimmunoassay
Bone Marrow
Western Blotting

Keywords

  • AML
  • MDS
  • Prognosis
  • VEGF
  • VEGF receptors

ASJC Scopus subject areas

  • Hematology

Cite this

Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome. / Verstovsek, Srdan; Estey, Elihu; Manshouri, Taghi; Giles, Francis J.; Cortes, Jorge; Beran, Miloslav; Rogers, Anna; Keating, Michael; Kantarjian, Hagop; Albitar, Maher.

In: British Journal of Haematology, Vol. 118, No. 1, 27.07.2002, p. 151-156.

Research output: Contribution to journalArticle

Verstovsek, S, Estey, E, Manshouri, T, Giles, FJ, Cortes, J, Beran, M, Rogers, A, Keating, M, Kantarjian, H & Albitar, M 2002, 'Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome', British Journal of Haematology, vol. 118, no. 1, pp. 151-156. https://doi.org/10.1046/j.1365-2141.2002.03551.x
Verstovsek, Srdan ; Estey, Elihu ; Manshouri, Taghi ; Giles, Francis J. ; Cortes, Jorge ; Beran, Miloslav ; Rogers, Anna ; Keating, Michael ; Kantarjian, Hagop ; Albitar, Maher. / Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome. In: British Journal of Haematology. 2002 ; Vol. 118, No. 1. pp. 151-156.
@article{62f9f232a8bf4093abbea18e828efa1b,
title = "Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome",
abstract = "We have previously reported that high levels of cellular vascular endothelial growth factor (VEGF) protein correlated with short survival of patients with acute myeloid leukaemia (AML). As VEGF exerts its effects via two receptors, VEGF receptor 1 (VEGFR-1) and VEGFR-2, we evaluated the significance of VEGFR-1 and VEGFR-2 protein levels in AML and myelodysplastic syndrome (MDS), and their relationship to VEGF protein levels. Western blot analysis and radioimmunoassay confirmed and quantified specific protein levels in bone marrow samples from 41 MDS and 66 AML previously untreated patients. VEGFR-1 levels were significantly higher in AML than in MDS (P = 0.0004), but no significant difference was found in the VEGFR-2 levels (P = 0.5). No significant correlation between VEGFRs levels and duration of survival was found. VEGF protein levels were significantly higher in MDS than in AML (P < 0.0001). A Cox proportional-hazard regression model showed increasing VEGF levels to significantly correlate with shorter survival of patients with MDS (P = 0.008), a finding similar to our previous report of the inverse relationship between VEGF levels and survival of AML patients. We found a significant correlation between VEGF and VEGFR-2 levels in both AML and MDS (P < 0.0000001 and P < 0.0002 respectively) but not between VEGF and VEGFR-1 levels. These data suggest that VEGF expression, rather than the expression of its receptors, is the determining factor in the biological behaviour of AML and MDS, and that VEGFRs are differentially expressed in AML and MDS.",
keywords = "AML, MDS, Prognosis, VEGF, VEGF receptors",
author = "Srdan Verstovsek and Elihu Estey and Taghi Manshouri and Giles, {Francis J.} and Jorge Cortes and Miloslav Beran and Anna Rogers and Michael Keating and Hagop Kantarjian and Maher Albitar",
year = "2002",
month = "7",
day = "27",
doi = "10.1046/j.1365-2141.2002.03551.x",
language = "English (US)",
volume = "118",
pages = "151--156",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome

AU - Verstovsek, Srdan

AU - Estey, Elihu

AU - Manshouri, Taghi

AU - Giles, Francis J.

AU - Cortes, Jorge

AU - Beran, Miloslav

AU - Rogers, Anna

AU - Keating, Michael

AU - Kantarjian, Hagop

AU - Albitar, Maher

PY - 2002/7/27

Y1 - 2002/7/27

N2 - We have previously reported that high levels of cellular vascular endothelial growth factor (VEGF) protein correlated with short survival of patients with acute myeloid leukaemia (AML). As VEGF exerts its effects via two receptors, VEGF receptor 1 (VEGFR-1) and VEGFR-2, we evaluated the significance of VEGFR-1 and VEGFR-2 protein levels in AML and myelodysplastic syndrome (MDS), and their relationship to VEGF protein levels. Western blot analysis and radioimmunoassay confirmed and quantified specific protein levels in bone marrow samples from 41 MDS and 66 AML previously untreated patients. VEGFR-1 levels were significantly higher in AML than in MDS (P = 0.0004), but no significant difference was found in the VEGFR-2 levels (P = 0.5). No significant correlation between VEGFRs levels and duration of survival was found. VEGF protein levels were significantly higher in MDS than in AML (P < 0.0001). A Cox proportional-hazard regression model showed increasing VEGF levels to significantly correlate with shorter survival of patients with MDS (P = 0.008), a finding similar to our previous report of the inverse relationship between VEGF levels and survival of AML patients. We found a significant correlation between VEGF and VEGFR-2 levels in both AML and MDS (P < 0.0000001 and P < 0.0002 respectively) but not between VEGF and VEGFR-1 levels. These data suggest that VEGF expression, rather than the expression of its receptors, is the determining factor in the biological behaviour of AML and MDS, and that VEGFRs are differentially expressed in AML and MDS.

AB - We have previously reported that high levels of cellular vascular endothelial growth factor (VEGF) protein correlated with short survival of patients with acute myeloid leukaemia (AML). As VEGF exerts its effects via two receptors, VEGF receptor 1 (VEGFR-1) and VEGFR-2, we evaluated the significance of VEGFR-1 and VEGFR-2 protein levels in AML and myelodysplastic syndrome (MDS), and their relationship to VEGF protein levels. Western blot analysis and radioimmunoassay confirmed and quantified specific protein levels in bone marrow samples from 41 MDS and 66 AML previously untreated patients. VEGFR-1 levels were significantly higher in AML than in MDS (P = 0.0004), but no significant difference was found in the VEGFR-2 levels (P = 0.5). No significant correlation between VEGFRs levels and duration of survival was found. VEGF protein levels were significantly higher in MDS than in AML (P < 0.0001). A Cox proportional-hazard regression model showed increasing VEGF levels to significantly correlate with shorter survival of patients with MDS (P = 0.008), a finding similar to our previous report of the inverse relationship between VEGF levels and survival of AML patients. We found a significant correlation between VEGF and VEGFR-2 levels in both AML and MDS (P < 0.0000001 and P < 0.0002 respectively) but not between VEGF and VEGFR-1 levels. These data suggest that VEGF expression, rather than the expression of its receptors, is the determining factor in the biological behaviour of AML and MDS, and that VEGFRs are differentially expressed in AML and MDS.

KW - AML

KW - MDS

KW - Prognosis

KW - VEGF

KW - VEGF receptors

UR - http://www.scopus.com/inward/record.url?scp=0036062374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036062374&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2141.2002.03551.x

DO - 10.1046/j.1365-2141.2002.03551.x

M3 - Article

C2 - 12100142

AN - SCOPUS:0036062374

VL - 118

SP - 151

EP - 156

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 1

ER -